Biotech has recently completed its Phase 2 trials of its revolutionary new Drug during 2017. On January 1, 2018, Biotech and Pharma entered into the License and Collaboration Agreement (LCA) under which Pharma licensed the rights to the Drug for future commercialization. Additionally, under the LCA, Biotech agreed to conduct the Phase 3 studies and submit the New Drug Application with the FDA if the Phase 3 results are positive. If approved by the FDA, Pharma is then responsible for all activities related to commercialization (production of Drug, marketing, sales and distribution). Pharma has agreed to pay Biotech as follows:
Biotech commenced P3 trials in January 2018, with total expected costs of $50 million in 2018 and $25 million in 2019. Actual costs were in line with estimates. The P3 results were concluded at the end of 2019 with positive results. In Q1 2020, Biotech submitted the NDA with the FDA, and approval was obtained in Q2 2021. Pharma launched Drug in Q1 2022. Net sales totaled $300 million in 2022 and $600 million in 2023.
Due to the significant uncertainties involved with drug development and the significance of possible reversal of revenues, Biotech believes that it would be inappropriate to include contingent consideration based on any expectations of positive P3 results or FDA approval until such events occur. However, if P3 results are positive, then Biotech did not have any reason to doubt that it would file the NDA. Additionally, with FDA approval, Pharma was required to commercially launch Drug, or else it would lose its rights to the license (and Biotech could then sell it to another company).
Biotech has estimated the relative fair values of the license and P3 studies to be $160 million and $80 million, respectively. Biotech has concluded that granting the license and conducting the P3 studies are each performance obligations. Additionally, the license was for a right to use functional IP that was delivered in January 2018.
REQUIRED: Determine the appropriate revenue recognition for each year from 2018 to 2023. Please also indicate to which performance obligation such revenue would be allocated. Please consider the guidance for the allocation of variable consideration.
Delivering a high-quality product at a reasonable price is not enough anymore.
That’s why we have developed 5 beneficial guarantees that will make your experience with our service enjoyable, easy, and safe.
You have to be 100% sure of the quality of your product to give a money-back guarantee. This describes us perfectly. Make sure that this guarantee is totally transparent.Read more
Each paper is composed from scratch, according to your instructions. It is then checked by our plagiarism-detection software. There is no gap where plagiarism could squeeze in.Read more
Thanks to our free revisions, there is no way for you to be unsatisfied. We will work on your paper until you are completely happy with the result.Read more
Your email is safe, as we store it according to international data protection rules. Your bank details are secure, as we use only reliable payment systems.Read more
By sending us your money, you buy the service we provide. Check out our terms and conditions if you prefer business talks to be laid out in official language.Read more